Two Start-ups announce drug discovery collaboration
Confo Therapeutics and DyNAbind collaborate to Identify Novel GPCR-Modulating Compounds
The collaboration will combine ConfoBody™-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing and commercialization.
Commenting on the deal, Dr Christel Menet, Confo Therapeutics’ CSO, said: “This collaboration will leverage the combination of two cutting-edge technologies to expand our universe of hits on a GPCR previously thought to be intractable. We look forward to working with the DyNAbind team on this exciting project.”
Dr Michael Thompson, co-founder and CEO of DyNAbind added: “GPCRs are high-potential targets for drug discovery, but have been traditionally difficult to work with. Confo Therapeutics’ technology has proven itself to be a powerful tool for the stabilization of GPCRs in a particular conformation. Partnered with the increased signal-to-noise ratios seen with our Dynamic Library technology, we are in a strong position to identify drug candidates against this specific target. ”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.